4-Benzyloxyaniline

4-Benzyloxyaniline

SCHEMBL171449

Nc1ccc(OCc2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 1.00
RAB9A P51151 2/20 1.00
GAA P10253 1/20 1.00
MAPT P10636 1/20 1.00
MAOA P21397 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
L3MBTL1 Q9Y468 1/20 1.00
F2 P00734 1/20 0.67
PRSS1 P07477 1/20 0.67
LMNA P02545 1/20 0.67
CYP1A2 P05177 1/20 0.67
PTGS1 P23219 1/20 0.67
SLC6A2 P23975 1/20 0.67
CYP2C19 P33261 1/20 0.67
PTGS2 P35354 1/20 0.67
SLC6A3 Q01959 1/20 0.67
HIF1A Q16665 1/20 0.67
HDAC6 Q9UBN7 1/20 0.67
APP P05067 1/20 0.66
NPC1 O15118 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Benzyloxyaniline SCHEMBL5376217 0.98 MAOB (0.96) MAOBRAB9AGAAMAPTMAOA
4-Benzyloxyaniline SCHEMBL371743 0.98 MAOB (0.96) MAOBRAB9AGAAMAPTMAOA
SCHEMBL5045790 0.94 MAOB (0.89) MAOBRAB9AGAAMAPTMAOA
SCHEMBL6733465 0.94 MAOB (0.89) MAOBRAB9AGAAMAPTMAOA
SCHEMBL323938 0.91 MAOB (0.84) MAOBRAB9AGAAMAPTMAOA
4-Benzyloxyaniline SCHEMBL8216099 0.91 MAOB (0.82) MAOBRAB9AGAAMAPTMAOA
4-Benzyloxyaniline SCHEMBL5571271 0.91 MAOB (0.83) MAOBRAB9AGAAMAPTMAOA
SCHEMBL31542030 0.89 MAOB (0.80) MAOBRAB9AGAAMAPTMAOA
SCHEMBL5121663 0.89 MAOB (0.80) MAOBRAB9AGAAMAPTMAOA
SCHEMBL339813 0.89 LMNA (0.82) MAOBRAB9AGAAMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117645771-A Solvent-free high-low temperature resistant bulletproof composite matrix resin and preparation method thereof 上海鑫丰泰新材料科技有限公司 2024-03-05 CN claimed
CN-117586207-A Preparation method of ketoconazole side chain 浙江东亚药业股份有限公司 2024-02-23 CN claimed
CN-109153655-B Novel N-acylurea derivatives and compositions comprising the same for preventing or treating cardiovascular diseases 高丽大学校产学协力团 2022-09-30 CN claimed
CN-114685788-A Compound, resin composition, and laminate 财团法人工业技术研究院 2022-07-01 CN claimed
US-20220194928-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE UNIV KOREA RES & BUS FOUND (KR) 2022-06-23 US claimed
CN-109705799-B YASI epoxy organic imide silica gel and preparation method thereof 东华大学 2022-03-18 CN claimed
CN-114015044-A Colorless transparent polyimide resin film and preparation method thereof 山东中柔新材料有限公司 2022-02-08 CN claimed
CN-109852330-B 3, 5-diaminobenzoic acid type silicon-containing adhesive and preparation method thereof 东华大学 2022-01-11 CN claimed
CN-109722212-B Imide epoxy organic silica gel and preparation method thereof 福建省海钛智能科技有限公司 2021-12-28 CN claimed
CN-109852331-B 3, 5-bis (4-aminophenoxy) benzoic acid type organic silica gel and preparation method thereof 福建省海钛智能科技有限公司 2021-12-28 CN claimed
US-6562840-B1 Non-peptidic inhibitors of proteolytic enzymes such as urokinase 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-05-13 US claimed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US claimed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO claimed
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP claimed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US claimed
US-6291514-B1 Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-09-18 US claimed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO claimed
EP-0322643-B1 MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE BAYER AG (DE) 1991-07-24 EP claimed
US-4729950-A AROMATIC AMINE, PEROXIDASE, OXIDIZER, 2,3-DIHYDRO-1,4-PHTHALAZINEDIONE NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1988-03-08 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 MAOB 3386/4885RAB9A 2317/4885GAA 3980/4885
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 MAOB 628/4885RAB9A 1248/4885GAA 533/4885
US-20220194928-A1 NOVEL N-ACYLUREA DERIVATIVE AND COMPOSITION COMPRISING SAME FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE TLN1, TNNI3, PTK2 MAOB 3725/4885RAB9A 1229/4885GAA 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.